9,076 Shares in Johnson & Johnson $JNJ Purchased by Wealthquest Corp

Key Points

• Wealthquest Corp opened a new position in Johnson & Johnson during the fourth quarter, buying 9,076 shares valued at about $1.88 million.
• Institutional interest in J&J remains strong, with hedge funds and other investors adding to positions; overall, institutions own about 69.55% of the stock.
• The company continues to show solid fundamentals and shareholder returns, with Q1 earnings and revenue beating estimates and J&J also raising its quarterly dividend to $1.34 per share.

Wealthquest Corp bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,076 shares of the company's stock, valued at approximately $1,878,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares during the period. United Bank boosted its holdings in Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company's stock worth $1,539,000 after acquiring an additional 4,876 shares during the period. Sivia Capital Partners LLC boosted its holdings in Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock worth $896,000 after acquiring an additional 692 shares during the period. Wealth Group Ltd. boosted its holdings in Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock worth $226,000 after acquiring an additional 168 shares during the period. Finally, Schnieders Capital Management LLC. boosted its holdings in Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after acquiring an additional 6,584 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received favorable coverage for its diversified pharma and MedTech businesses, with analysts saying its pipeline progress and stronger 2026 outlook make it better positioned than Pfizer despite patent risks. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
• Positive Sentiment: The company announced China approval for nipocalimab, a regulatory win that expands the drug’s commercial potential and supports sentiment around J&J’s pipeline. Johnson & Johnson says nipocalimab approved in China
• Positive Sentiment: J&J also highlighted a next-generation coronary artery disease catheter, reinforcing growth prospects in its MedTech segment and ongoing innovation in interventional medicine. Johnson & Johnson (JNJ) Unveils Next-Gen Catheter for Coronary Artery Disease
• Positive Sentiment: J&J announced a collaboration to build a global intelligent operating room network with Abu Dhabi’s health department, adding another AI-driven MedTech initiative that could strengthen its long-term growth story. Johnson & Johnson Advances Creation of Global Intelligent OR Network
• Neutral Sentiment: J&J was included in broader dividend and blue-chip stock commentary, which may reinforce its reputation as a defensive income stock but does not appear to be a major direct driver. The Dividend Stocks That Can Replace a $65,000 Income and What They’ll Cost You
• Neutral Sentiment: Another article framed J&J as a defensive growth stock, supporting the bull case but offering little new fundamental information. Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case
• Negative Sentiment: ImmunityBio said its ANKTIVA-based bladder cancer data shows a cost advantage versus J&J’s TAR-200, which could raise competitive pressure in an important oncology area. IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J’s TAR-200

Analysts Set New Price Targets

A number of brokerages have issued reports on JNJ. Barclays upped their target price on Johnson & Johnson from $234.00 to $255.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 15th. Morgan Stanley set a $283.00 price target on Johnson & Johnson in a research report on Wednesday, April 15th. Royal Bank Of Canada reissued an "outperform" rating and set a $265.00 price target on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Johnson Rice raised Johnson & Johnson from a "hold" rating to an "outperform" rating in a research report on Wednesday, May 13th. Finally, Leerink Partners raised Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 price target on the stock in a research report on Wednesday, May 13th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.04.

Johnson & Johnson Trading Up 0.1%

Shares of JNJ stock opened at $234.67 on Monday. The stock has a 50-day simple moving average of $234.02 and a 200 day simple moving average of $223.54. Johnson & Johnson has a fifty-two week low of $149.04 and a fifty-two week high of $251.71. The stock has a market capitalization of $564.91 billion, a P/E ratio of 27.13, a P/E/G ratio of 2.29 and a beta of 0.27. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same quarter last year, the company posted $2.77 EPS. Johnson & Johnson's revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a $1.34 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. Johnson & Johnson's dividend payout ratio is 60.12%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.